Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to fill gaps in lymphoma care in africa

NCT ID NCT02835911

Knowledge-focused Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study is creating a large registry of 800 lymphoma patients in Malawi to collect detailed information about the disease. Researchers will perform biopsies and track patients over time to understand how lymphoma affects people in sub-Saharan Africa. The goal is to gather data that is currently missing, which could improve future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide crucial data on lymphoma in sub-Saharan Africa, potentially guiding better diagnosis and treatment strategies for the region.
What could go wrong
This is an observational registry, not a treatment trial, so it won't directly benefit participants. Data collection may face challenges like patient follow-up or limited resources.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,140 people

The number who actually took part.

Started

Apr 2013

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

800 patients with suspected lymphoma in Malawi.

Ages

0 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Criteria: Inclusion Criteria: * Referred to Kamuzu Central Hospital (KCH) with clinically suspected lymphoma based on clinical impression of referring providers Age \>5 years, or ≤5 years only if lymphoma has already been pathologically confirmed. * No prior or concurrent histologically confirmed cancer diagnosis or receipt of cancer treatment. * Residence \<200 kilometers from KCH. Able to understand and comply with study procedures for the entire length of the study, with assistance of parent or guardian as applicable. * Subject (or parent or guardian as applicable) able to understand and provide written consent in English or Chichewa. * Informed consent reviewed and signed by patient, or for pediatric patients, from parent or guardian. Exclusion Criteria: * There are no exclusion criteria other than failure to meet inclusion criteria listed above. * Patients may consent to participation in the study but refuse directed genomic analysis of their lymphoma specimens.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic malignancies Lymphoma

Contacts and locations

Locations

  • UNC Project

    Lilongwe, Malawi

More trials for these conditions

Other studies related to the condition(s) this trial covers.